Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cryoport, Inc. on June 23, 2011. The filing reports on executive leadership changes effective June 27, 2011, coinciding with the filing of the Company's Form 10-K for the fiscal year ended March 31, 2011.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
The primary material change is the appointment of Robert S. Stefanovich as Chief Financial Officer, Treasurer, and Corporate Secretary, replacing Ms. Catherine Doll, who resigned from the same positions.
- New CFO: Robert S. Stefanovich (effective June 27, 2011).
- Outgoing CFO: Catherine Doll (resignation effective June 27, 2011).
Compensation and Management Commentary
Mr. Stefanovich's compensation package includes:
- Base Salary: $225,000 annually.
- Incentive Bonus: Targeted at 25% of annual base salary.
- Stock Options: Grant of 125,000 shares at an exercise price of $0.93 per share (closing price on June 23, 2011).
- Vesting Schedule: Four years in eight equal six-month installments.
- Severance (Change of Control): 12 months of base salary, 12 months of health benefits, and immediate full vesting of unvested options.
- Severance (Termination without Cause): 6 months of base salary and 6 months of health benefits.
Mr. Stefanovich brings prior experience as CFO of Novalar Pharmaceuticals, Inc., and senior roles at Xcorporeal, Inc., Artemis International Solutions Corporation, and Aethlon Medical Inc.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 27, 2011) against the filing of the Form 10-K for the fiscal year ended March 31, 2011.
- Review the attached Press Release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Confirm the stock option grant details (125,000 shares at $0.93) in the Company's subsequent equity filings.
- Assess the impact of the new CFO's background in venture-backed and publicly traded medical device/pharmaceutical companies on Cryoport's financial strategy.